Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14841814 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CNR1CNR2 | |
| SCHEMBL16371215 | 0.96 | ALDH1A1 (0.55) | ALDH1A1CNR1CNR2 | |
| SCHEMBL17202309 | 0.96 | ALDH1A1 (0.55) | ALDH1A1CNR1CNR2 | |
| SCHEMBL14833984 | 0.96 | ALDH1A1 (0.55) | ALDH1A1CNR1CNR2 | |
| SCHEMBL15018493 | 0.96 | ALDH1A1 (0.55) | ALDH1A1CNR1CNR2 | |
| SCHEMBL15018073 | 0.96 | ALDH1A1 (0.55) | ALDH1A1CNR1CNR2 | |
| SCHEMBL28672467 | 0.96 | ALDH1A1 (0.55) | ALDH1A1CNR1CNR2 | |
| SCHEMBL21248542 | 0.96 | ALDH1A1 (0.55) | ALDH1A1CNR1CNR2 | |
| SCHEMBL20540819 | 0.96 | ALDH1A1 (0.55) | ALDH1A1CNR1CNR2 | |
| SCHEMBL17202356 | 0.96 | ALDH1A1 (0.55) | ALDH1A1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024073848-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19 | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2024-04-11 | — | — | WO | disclosed |
| EP-4337101-A1 | METHODS AND COMPOSITIONS FOR TREATING AGING AND CHRONIC DISEASE | L.E.A.F Holdings Group LLC (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2024015366-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | Arkea Bio Corp. (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-4225923-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19 | Providence Therapeutics Holdings Inc. (CA) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023137550-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF COVID-19 | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2023-07-27 | — | — | WO | disclosed |
| WO-2020097409-A9 | USE OF MRNA ENCODING OX40L TO TREAT CANCER IN HUMAN PATIENTS | MODERNATX, INC. (US) | 2020-06-18 | — | — | WO | disclosed |
| EP-3625345-A1 | MODIFIED MESSENGER RNA COMPRISING FUNCTIONAL RNA ELEMENTS | ModernaTX, Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3458105-A1 | POLYNUCLEOTIDES ENCODING GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE FOR THE TREATMENT OF GALACTOSEMIA TYPE 1 | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3458590-A1 | POLYNUCLEOTIDES ENCODING -GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3458081-A1 | POLYNUCLEOTIDES ENCODING CITRIN FOR THE TREATMENT OF CITRULLINEMIA TYPE 2 | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3458083-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| WO-2018213789-A1 | MODIFIED MESSENGER RNA COMPRISING FUNCTIONAL RNA ELEMENTS | MODERNATX, INC. (US) | 2018-11-22 | — | — | WO | disclosed |
| WO-2017201328-A1 | POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201332-A1 | POLYNUCLEOTIDES ENCODING ACYL-COA DEHYDROGENASE, VERY LONG-CHAIN FOR THE TREATMENT OF VERY LONG-CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201348-A1 | POLYNUCLEOTIDES ENCODING GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE FOR THE TREATMENT OF GALACTOSEMIA TYPE 1 | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201349-A1 | POLYNUCLEOTIDES ENCODING CITRIN FOR THE TREATMENT OF CITRULLINEMIA TYPE 2 | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201350-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |